Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to stop postpartum bleeding in At-Risk moms

NCT ID NCT07353281

Prevention Sponsor: Western Galilee Hospital-Nahariya Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two medicines—carbetocin (given through a vein) and misoprostol (given as a rectal tablet)—to see which works better at preventing dangerous heavy bleeding after vaginal delivery in women with risk factors. About 146 women will take part. The goal is to find the safest, most effective way to protect mothers from postpartum hemorrhage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 146 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Women aged 18 years or older * Singleton pregnancy * Gestational age 37-42 weeks * Cephalic presentation * Vaginal delivery * Presence of one or more risk factors for postpartum hemorrhage, including: * Grand multiparity (≥5 previous deliveries) * History of postpartum hemorrhage * History of manual removal of placenta * Estimated fetal weight ≥4,000 grams * Polyhydramnios * Chorioamnionitis * Prolonged oxytocin use during labor (third augmentation cycle or more) * Eligible for prophylactic uterotonic therapy after delivery * Provided written informed consent Exclusion Criteria * Multiple gestation * Known major fetal anomalies * Intrauterine fetal demise (IUFD) * Contraindication to vaginal delivery * Known hypersensitivity to carbetocin, misoprostol, or oxytocin * Known coagulation disorders requiring alternative management * Planned cesarean delivery * Participation in another interventional study that may affect postpartum bleeding outcomes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Postpartum complication are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Postpartum Hemorrhage puerperal disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postpartum complication Postpartum hemorrhage

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.